Iterum Therapeutics Appoints Sailaja Puttagunta, MD as Chief Medical Officer
December 13 2021 - 8:00AM
Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”),
a clinical-stage pharmaceutical company focused on developing next
generation oral and IV antibiotics to treat infections caused by
multi-drug resistant pathogens in both community and hospital
settings, today announced the appointment of Sailaja
Puttagunta, M.D., to the newly created position of Chief Medical
Officer, where she will oversee global clinical development and
regulatory initiatives for Iterum.
“We are thrilled that Sailaja is back at Iterum given her strong
industry and operational leadership at a time when oral sulopenem
is re-entering the clinic,” said Corey Fishman, Chief
Executive Officer of Iterum. “Sailaja has deep experience in
antibiotic drug development, including having previously worked on
sulopenem at both Iterum and Pfizer Inc., which will prove
invaluable for our clinical development and registration
strategies. She has dedicated her career as a clinician and
practicing Infectious Disease physician to making a difference in
patients’ lives and is strongly aligned with our belief that
sulopenem is a much-needed therapy.”
“I’m excited to rejoin Iterum at this time of important
advancement for the Company,” said Dr. Puttagunta. “I truly believe
that sulopenem has the potential to effectively treat the growing
problem of multi-drug resistant infections in both hospital and
community settings. I look forward to helping Iterum continue to
accelerate the development of sulopenem.”
Dr. Puttagunta, brings more than 20 years of clinical, academic
and research experience in medicine and the sub-specialty of
Infectious Diseases, including the approval of several antibiotic
medicines and previously served as Vice President of Clinical
Development at Iterum from 2016 to 2018. Most recently Dr.
Puttagunta served as Chief Medical Officer at BiomX Inc., a public
biotechnology company. Dr. Puttagunta graduated from Gandhi Medical
College in Hyderabad, India and completed her residency
in Internal Medicine and a fellowship in Infectious Diseases
at Yale University School of Medicine. She also holds an M.S.
in Biochemistry from the New York University School of
Medicine.
About Iterum Therapeutics
plc
Iterum Therapeutics plc is a clinical-stage
pharmaceutical company dedicated to developing differentiated
anti-infectives aimed at combatting the global crisis of multi-drug
resistant pathogens to significantly improve the lives of people
affected by serious and life-threatening diseases around the world.
Iterum is advancing its first compound, sulopenem, a novel penem
anti-infective compound, in Phase 3 clinical development with an
oral formulation and IV formulation. Sulopenem has demonstrated
potent in vitro activity against a wide variety of gram-negative,
gram-positive and anaerobic bacteria resistant to other
antibiotics. Iterum has received Qualified Infectious Disease
Product (QIDP) and Fast Track designations for its oral and IV
formulations of sulopenem in seven indications.
Forward-Looking Statements
This press release contains forward-looking
statements. In some cases, forward-looking statements can be
identified by words such as “may,” “believes,” “intends,” “seeks,”
“anticipates,” “plans,” “estimates,” “expects,” “should,”
“assumes,” “continues,” “could,” “would,” “will,” “future,”
“potential” or the negative of these or similar terms and phrases.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the Company’s actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking statements. Forward-looking
statements include all matters that are not historical facts.
Actual future results may be materially different from what is
expected due to factors largely outside the Company’s control,
including uncertainties inherent in the initiation and conduct of
clinical and nonclinical development, including any additional
trials that may be conducted in response to the complete response
letter received by the Company in July 2021, availability and
timing of data from such clinical and nonclinical development,
changes in regulatory requirements or decisions of regulatory
authorities, the timing or likelihood of regulatory filings and
approvals, including any potential resubmission of the new drug
application for oral sulopenem, changes in public policy or
legislation, commercialization plans and timelines, if oral
sulopenem is approved, the actions of third-party clinical research
organizations, suppliers and manufacturers, the accuracy of the
Company’s expectations regarding how far into the future the
Company’s cash on hand will fund the Company’s ongoing operations,
the impact of COVID-19 and related responsive measures thereto,
risks and uncertainties concerning the outcome, impact, effects and
results of the Company’s evaluation of corporate, strategic,
financial and financing alternatives, including the terms, timing,
structure, value, benefits and costs of any corporate, strategic,
financial or financing alternative and the Company’s ability to
complete one at all and other factors discussed under the caption
“Risk Factors” in its Quarterly Report on Form 10- Q filed with the
Securities and Exchange Commission (the “SEC”) on November 12,
2021, and other documents filed with the SEC from time to time.
Forward-looking statements represent the Company’s beliefs and
assumptions only as of the date of this press release. Except as
required by law, the Company assumes no obligation to update these
forward-looking statements publicly, or to update the reasons
actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future.
Investor Contact:Judy Matthews Chief
Financial Officer312-778-6073IR@iterumtx.com
Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart
From Sep 2023 to Sep 2024